Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.83)
# 450
Out of 4,698 analysts
398
Total ratings
51.4%
Success rate
19.3%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintained: Buy | $332 | $285.60 | +16.25% | 9 | Aug 14, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $40 | $12.17 | +228.68% | 12 | Aug 14, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $34.60 | $11.64 | +197.22% | 4 | Aug 12, 2026 | |
| MBX MBX Biosciences | Maintained: Buy | $56 → $70 | $61.72 | +13.42% | 11 | Aug 11, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $30 | $17.26 | +73.81% | 25 | Aug 7, 2026 | |
| GPCR Structure Therapeutics | Maintained: Buy | $90 | $47.34 | +90.11% | 9 | Aug 7, 2026 | |
| EOLS Evolus | Reiterated: Buy | $17 | $9.30 | +82.80% | 27 | Aug 6, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $230 → $275 | $246.81 | +11.42% | 42 | Aug 4, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | $95 | $34.87 | +172.44% | 25 | Jul 30, 2026 | |
| IVA Inventiva | Reiterated: Buy | $15 | $4.78 | +213.81% | 18 | Jul 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $4.58 | +773.36% | 1 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $8.94 | +369.80% | 26 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 | $157.24 | +58.99% | 9 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $28.21 | +84.33% | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $55 | $43.53 | +26.35% | 31 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 | $9.50 | +194.74% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.42 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $0.8653 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2,491.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.91 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $8.55 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.76 → $19.37 | $9.06 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.0077 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $2.41 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $5 | $2.21 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $14.92 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $7.99 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $111.62 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $15.82 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $37.07 | n/a | 1 | Oct 18, 2011 |
Ligand Pharmaceuticals
Aug 14, 2026
Maintained: Buy
Price Target: $332
Current: $285.60
Upside: +16.25%
Oculis Holding AG
Aug 14, 2026
Maintained: Buy
Price Target: $40
Current: $12.17
Upside: +228.68%
Eupraxia Pharmaceuticals Inc.
Aug 12, 2026
Reiterated: Buy
Price Target: $34.60
Current: $11.64
Upside: +197.22%
MBX Biosciences
Aug 11, 2026
Maintained: Buy
Price Target: $56 → $70
Current: $61.72
Upside: +13.42%
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $30
Current: $17.26
Upside: +73.81%
Structure Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $90
Current: $47.34
Upside: +90.11%
Evolus
Aug 6, 2026
Reiterated: Buy
Price Target: $17
Current: $9.30
Upside: +82.80%
Jazz Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $230 → $275
Current: $246.81
Upside: +11.42%
Viking Therapeutics
Jul 30, 2026
Maintained: Buy
Price Target: $95
Current: $34.87
Upside: +172.44%
Inventiva
Jul 20, 2026
Reiterated: Buy
Price Target: $15
Current: $4.78
Upside: +213.81%
Jul 16, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $4.58
Upside: +773.36%
Jun 25, 2026
Reiterated: Buy
Price Target: $42
Current: $8.94
Upside: +369.80%
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $157.24
Upside: +58.99%
May 7, 2026
Maintained: Buy
Price Target: $52
Current: $28.21
Upside: +84.33%
May 6, 2026
Maintained: Hold
Price Target: $55
Current: $43.53
Upside: +26.35%
Jan 15, 2026
Maintained: Buy
Price Target: $28
Current: $9.50
Upside: +194.74%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.42
Upside: -
Apr 1, 2025
Maintained: Buy
Price Target: $8
Current: $0.8653
Upside: n/a
Jan 8, 2025
Maintained: Buy
Price Target: n/a
Current: $2,491.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.91
Upside: n/a
Aug 30, 2023
Maintained: Hold
Price Target: $11
Current: $8.55
Upside: n/a
Nov 3, 2022
Maintained: Buy
Price Target: $20.76 → $19.37
Current: $9.06
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.0077
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $2.41
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $5
Current: $2.21
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $14.92
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $7.99
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $111.62
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $15.82
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $37.07
Upside: n/a